伴有合并症的慢性淋巴细胞白血病患者接受苯丁酸氮芥联合奥滨尤妥珠单抗或利妥昔单抗治疗后微小残留病灶的预后价值。
Prognostic value of MRD in CLL patients with comorbidities receiving chlorambucil plus obinutuzumab or rituximab.
机构信息
Department of Immunology, Laboratory for Medical Immunology, Erasmus University Medical Center, Rotterdam, The Netherlands.
Department of Hematology, University of Schleswig-Holstein, Kiel, Germany.
出版信息
Blood. 2019 Jan 31;133(5):494-497. doi: 10.1182/blood-2018-03-839688. Epub 2018 Nov 19.
Abstract
There is a Commentary on this article in this issue.
摘要
本期对这篇文章有评论。
相似文献
1
Prognostic value of MRD in CLL patients with comorbidities receiving chlorambucil plus obinutuzumab or rituximab.伴有合并症的慢性淋巴细胞白血病患者接受苯丁酸氮芥联合奥滨尤妥珠单抗或利妥昔单抗治疗后微小残留病灶的预后价值。
Blood. 2019 Jan 31;133(5):494-497. doi: 10.1182/blood-2018-03-839688. Epub 2018 Nov 19.
2
Obinutuzumab treatment in the elderly patient with chronic lymphocytic leukemia.奥妥珠单抗治疗老年慢性淋巴细胞白血病患者
Clin Interv Aging. 2015 Jun 12;10:951-61. doi: 10.2147/CIA.S69278. eCollection 2015.
3
Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions.奥滨尤妥珠单抗联合苯丁酸氮芥治疗伴有合并症的 CLL 患者。
N Engl J Med. 2014 Mar 20;370(12):1101-10. doi: 10.1056/NEJMoa1313984. Epub 2014 Jan 8.
4
Real-world data on efficacy and safety of obinutuzumab plus chlorambucil, rituximab plus chlorambucil, and rituximab plus bendamustine in the frontline treatment of chronic lymphocytic leukemia: The GO-CLLEAR Study by the Czech CLL Study Group.真实世界研究中奥滨尤妥珠单抗联合苯丁酸氮芥、利妥昔单抗联合苯丁酸氮芥和利妥昔单抗联合苯达莫司汀在慢性淋巴细胞白血病一线治疗中的疗效和安全性：捷克 CLL 研究组的 GO-CLLEAR 研究。
Hematol Oncol. 2020 Oct;38(4):509-516. doi: 10.1002/hon.2744. Epub 2020 Jun 1.
5
Obinutuzumab: a novel anti-CD20 monoclonal antibody for previously untreated chronic lymphocytic leukemia.奥滨尤妥珠单抗：一种用于既往未治疗的慢性淋巴细胞白血病的新型抗CD20单克隆抗体。
Ann Pharmacother. 2014 Oct;48(10):1356-61. doi: 10.1177/1060028014543271. Epub 2014 Jul 18.
6
[Current diagnosis and treatment of chronic lymphocytic leukaemia].[慢性淋巴细胞白血病的当前诊断与治疗]
Dtsch Med Wochenschr. 2020 Aug;145(16):1139-1144. doi: 10.1055/a-1039-8472. Epub 2020 Aug 13.
7
Management of patients with previously untreated chronic lymphocytic leukaemia with obinutuzumab and chlorambucil.用奥妥珠单抗和苯丁酸氮芥治疗既往未经治疗的慢性淋巴细胞白血病患者
Intern Med J. 2017 Jul;47 Suppl 4:5-10. doi: 10.1111/imj.13493.
8
Role of obinutuzumab in the treatment of chronic lymphocytic leukemia.奥滨尤妥珠单抗在慢性淋巴细胞白血病治疗中的作用。
Am J Health Syst Pharm. 2015 Jun 1;72(11):933-42. doi: 10.2146/ajhp140282.
9
Obinutuzumab for the treatment of chronic lymphocytic leukemia.奥滨尤妥珠单抗用于治疗慢性淋巴细胞白血病。
Drugs Today (Barc). 2014 Jun;50(6):407-19. doi: 10.1358/dot.2014.50.6.2138702.
10
Obinutuzumab looks impressive in CLL.奥滨尤妥珠单抗在慢性淋巴细胞白血病中表现出色。
Cancer Discov. 2014 Apr;4(4):OF5. doi: 10.1158/2159-8290.CD-NB2014-024. Epub 2014 Feb 13.
引用本文的文献
1
Long-term outcomes of chemoimmunotherapy with obinutuzumab/chlorambucil in chronic lymphocytic leukemia.奥妥珠单抗/苯丁酸氮芥化学免疫疗法治疗慢性淋巴细胞白血病的长期疗效
Blood Adv. 2025 May 27;9(10):2431-2435. doi: 10.1182/bloodadvances.2024014875.
2
Flow Cytometric MRD Detection in Selected Mature B-Cell Malignancies.流式细胞术微小残留病灶检测在特定成熟 B 细胞恶性肿瘤中的应用。
Methods Mol Biol. 2025;2865:145-188. doi: 10.1007/978-1-0716-4188-0_7.
3
Molecular techniques in haematopathology: what and how?血液病理学中的分子技术：是什么以及如何应用？
Histopathology. 2025 Jan;86(1):38-57. doi: 10.1111/his.15332. Epub 2024 Oct 15.
4
Chronic Lymphocytic Leukemia: Prognostic Factors in the Era of Novel Drugs.慢性淋巴细胞白血病：新药时代的预后因素
Cancers (Basel). 2024 Jul 31;16(15):2732. doi: 10.3390/cancers16152732.
5
Leveraging genomics, transcriptomics and epigenomics to understand chemoimmunotherapy resistance in chronic lymphocytic leukemia.利用基因组学、转录组学和表观基因组学来了解慢性淋巴细胞白血病中的化疗免疫治疗耐药性。
Cancer Drug Resist. 2024 Feb 28;7:7. doi: 10.20517/cdr.2023.98. eCollection 2024.
6
Chronic Lymphocytic Leukemia: Time-Limited Therapy in the First-Line Setting and Role of Minimal Residual Disease.慢性淋巴细胞白血病：一线治疗中的限时疗法和微小残留病的作用。
Curr Oncol Rep. 2024 Feb;26(2):136-146. doi: 10.1007/s11912-023-01482-6. Epub 2024 Jan 4.
7
Unresolved questions in selection of therapies for treatment-naïve chronic lymphocytic leukemia.治疗初治慢性淋巴细胞白血病的治疗方法选择中存在的未解决问题。
J Hematol Oncol. 2023 Jul 8;16(1):72. doi: 10.1186/s13045-023-01469-7.
8
Early-stage measurable residual disease dynamics and IGHV repertoire reconstitution during venetoclax and obinutuzumab treatment in chronic lymphocytic leukemia.慢性淋巴细胞白血病患者在接受维奈克拉和奥妥珠单抗治疗期间的早期可测量残留病动态及IGHV基因库重建
Blood Cancer J. 2023 Jul 4;13(1):102. doi: 10.1038/s41408-023-00870-2.
9
Transcriptomic profiles and 5-year results from the randomized CLL14 study of venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab in chronic lymphocytic leukemia.CLL14 研究的转录组谱和 5 年结果：venetoclax 联合 obinutuzumab 对比氯苯丁酸联合 obinutuzumab 用于慢性淋巴细胞白血病。
Nat Commun. 2023 Apr 18;14(1):2147. doi: 10.1038/s41467-023-37648-w.
10
Patient specific real-time PCR in precision medicine - Validation of IG/TR based MRD assessment in lymphoid leukemia.精准医学中的患者特异性实时PCR——基于IG/TR的淋巴白血病微小残留病评估的验证
Front Oncol. 2023 Jan 16;12:1111209. doi: 10.3389/fonc.2022.1111209. eCollection 2022.
本文引用的文献
1
A model for predicting effect of treatment on progression-free survival using MRD as a surrogate end point in CLL.使用 MRD 作为 CLL 替代终点预测治疗对无进展生存期影响的模型。
Blood. 2018 Mar 1;131(9):955-962. doi: 10.1182/blood-2017-06-792333. Epub 2017 Dec 18.
2
Use of minimal residual disease assessment in the treatment of chronic lymphocytic leukemia.微小残留病评估在慢性淋巴细胞白血病治疗中的应用。
Leuk Lymphoma. 2017 Dec;58(12):2777-2785. doi: 10.1080/10428194.2017.1318439. Epub 2017 May 16.
3
NCCN Guidelines Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 1.2017.NCCN 指南解读：慢性淋巴细胞白血病/小淋巴细胞淋巴瘤，第 1.2017 版。
J Natl Compr Canc Netw. 2017 Mar;15(3):293-311. doi: 10.6004/jnccn.2017.0030.
4
Minimal residual disease is an independent predictor for 10-year survival in CLL.微小残留病是 CLL 患者 10 年生存的独立预测因子。
Blood. 2016 Dec 15;128(24):2770-2773. doi: 10.1182/blood-2016-05-714162. Epub 2016 Oct 3.
5
Minimal Residual Disease Provides Treatment Focus for Next Chronic Lymphocytic Leukemia Advances.微小残留病为慢性淋巴细胞白血病的下一步进展提供治疗重点。
J Clin Oncol. 2016 Nov 1;34(31):3722-3723. doi: 10.1200/JCO.2016.69.1972.
6
Minimal Residual Disease Assessment Improves Prediction of Outcome in Patients With Chronic Lymphocytic Leukemia (CLL) Who Achieve Partial Response: Comprehensive Analysis of Two Phase III Studies of the German CLL Study Group.微小残留病灶评估改善慢性淋巴细胞白血病（CLL）患者达部分缓解患者的预后预测：德国 CLL 研究组两项 III 期研究的综合分析。
J Clin Oncol. 2016 Nov 1;34(31):3758-3765. doi: 10.1200/JCO.2016.67.1305.
7
Obinutuzumab: A Novel Anti-CD20 Monoclonal Antibody for Chronic Lymphocytic Leukemia.奥妥珠单抗：一种用于慢性淋巴细胞白血病的新型抗CD20单克隆抗体。
J Adv Pract Oncol. 2015 Jul-Aug;6(4):370-4. doi: 10.6004/jadpro.2015.6.4.7. Epub 2015 Jul 1.
8
Management of Chronic Lymphocytic Leukemia in the Elderly.老年慢性淋巴细胞白血病的管理
Cancer Control. 2015 Oct;22(4 Suppl):17-23. doi: 10.1177/107327481502204s04.
9
Eliminating minimal residual disease as a therapeutic end point: working toward cure for patients with CLL.将清除微小残留病作为治疗终点：致力于实现慢性淋巴细胞白血病患者的治愈
Blood. 2016 Jan 21;127(3):279-86. doi: 10.1182/blood-2015-08-634816. Epub 2015 Nov 17.
10
Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.慢性淋巴细胞白血病：ESMO诊断、治疗及随访临床实践指南
Ann Oncol. 2015 Sep;26 Suppl 5:v78-84. doi: 10.1093/annonc/mdv303.
Zotero 插件